Decision Resources, Inc., one of the world's leading research and advisory firms for pharmaceutical and health care issues, finds that the Medicare Modernization Act will increase screening for dyslipidemia in Medicare enrollees 65 and older by including coverage for a routine medical exam. The physical exam includes blood tests aimed at early detection of cardiovascular disease, including measurement of cholesterol levels and other lipid subfractions.

The new PhysicianForum primary market research report entitled Dynamics in Dyslipidemia: Impact of Patent Expiries and New Products also finds that Merck's Zocor and Bristol-Myers Squibb's Pravachol will be dropped from many HMO formularies once their patents expire in 2006.

"Following patent expirations for the popular statins Zocor and Pravachol in 2006, the majority of HMO pharmacy directors surveyed say that these brands will be reallocated to tier 3 or dropped from their product formularies and that generic simvastatin and pravastatin will be found on tier 1," said Ruth Brown, analyst at Decision Resources. "Changes could also affect positioning of Pfizer's Lipitor in some cases. Sixty-seven percent of HMO pharmacy directors also say they will introduce a stepped-care approach to therapy for dyslipidemia post 2006."

Dynamics in Dyslipidemia: Impact of Patent Expiries and New Products is based on a U.S. survey of 18 HMO pharmacy directors, 78 cardiologists, and 75 primary care physicians (PCPs). Their responses were compared to assess similarities and differences of opinion regarding clinical, economic, and scientific factors.

About PhysicianForum

PhysicianForum is a primary research service from Decision Resources that offers access to high volume-prescribing PCPs, specialists, and managed care organization representatives in the United States. PhysicianForum offers analysis of events and survey participants' responses to them; insight into prescribing patterns; and an examination of the implications of events and issues for the pharmaceutical market.

About Decision Resources

Decision Resources, Inc. ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc.,

Marketed and Emerging Biologic Agents Will Be the Greatest Drivers of Sales Growth in the Rheumatoid Arthritis Drug Market

View Now